bio

Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors

July 02, 2025 06:00 ET  | Source: Instil Bio US phase 1 trial of ‘2510 is expected to be initiated before…

1 day ago

Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy

July 02, 2025 03:00 ET  | Source: Belite Bio, Inc -  500 subjects enrolled across the United States, the United…

1 day ago

Verdiva Bio to Present New Data Highlighting Once-Weekly Potential of Its Investigational Oral Obesity Candidates at the ADA 85th Scientific Sessions

Phase 1 data evaluating VRB-101, Verdiva Bio’s cAMP-biased oral GLP-1RA, provides proof of concept for potential once-weekly oral administration. Preclinical…

2 weeks ago

Saudi Arabia Concludes Landmark BIO 2025 Debut as Kingdom Opens Doors to Global Biotech Collaboration

BOSTON, June 20, 2025 (GLOBE NEWSWIRE) -- Saudi Arabia has concluded its landmark debut at the BIO International Convention 2025,…

2 weeks ago

Parataxis Holdings LLC Announces Definitive Agreement with Bridge Biotherapeutics, Inc. (KOSDAQ: 288330), to Bring Institutionally-Backed, Bitcoin Treasury Company to the South Korean Public Markets:

SEOUL, South Korea and NEW YORK, June 20, 2025 /PRNewswire/ -- Parataxis Holdings LLC ("Parataxis Holdings"), an affiliate of Parataxis Capital…

2 weeks ago

TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 06, 2025 16:05 ET  | Source: TELA Bio, Inc. MALVERN, Pa., June 06, 2025 (GLOBE NEWSWIRE) -- TELA Bio,…

4 weeks ago

Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

June 05, 2025 16:58 ET  | Source: Boundless Bio, Inc. SAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) -- Boundless Bio…

4 weeks ago